Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 10/2007

01-10-2007 | Editorial

Adherence to treatment of osteoporosis: a need for study

Authors: F. Lekkerkerker, J. A. Kanis, N. Alsayed, G. Bouvenot, N. Burlet, D. Cahall, A. Chines, P. Delmas, R.-L. Dreiser, D. Ethgen, N. Hughes, J.-M. Kaufman, S. Korte, G. Kreutz, A. Laslop, B. Mitlak, V. Rabenda, R. Rizzoli, A. Santora, R. Schimmer, Y. Tsouderos, P. Viethel, J.-Y. Reginster

Published in: Osteoporosis International | Issue 10/2007

Login to get access

Abstract

Summary

Adherence to anti-osteoporosis medications is currently low and is associated with poor anti-fracture efficacy. This manuscript reviews the potential design of clinical studies that aim to demonstrate improved adherence, with new chemical entities to be used in the management of osteoporosis.

Introduction

Several medications have been unequivocally shown to decrease fracture rates in clinical trials. However, in real life settings, long-term persistence and compliance to anti-osteoporosis medication is poor, hence decreasing the clinical benefits for patients.

Methods

An extensive search of Medline from 1985 to 2006 retrieved all trials including the keywords osteoporosis, compliance, persistence or adherence followed by a critical appraisal of the data obtained through a consensus expert meeting.

Results

The impact of non-adherence on the clinical development of interventions is reviewed, so that clinicians, regulatory agencies and reimbursement agencies might be better informed of the problem, in order to stimulate the necessary research to document adherence.

Conclusion

Adherence to therapy is a major problem in the treatment of osteoporosis. Both patients and medication factors are involved. Adherence studies are an important aspect of outcomes studies, but study methodologies are not well developed at the moment and should be improved. Performing adherence studies will be stimulated when registration authorities accept the result of these studies and include the relevant information in Sect. 5.1 of the summary of product characteristics. Reimbursement authorities might also consider such studies as important information for decisions on reimbursement.
Literature
1.
Caro JJ, Ishak KJ, Huybrechts KF et al (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporosis Int 15:1003–1008CrossRef
2.
Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38:922–928PubMedCrossRef
3.
Siris ES, Harris ST, Rosen CJ et al (2006) Adherence to bisphosphonate therapy and fracture rtes in osteoporotic women: relationship to vertebral and non-vertebral fractures from 2 US claims databases. Mayo Clinic Proc 81:1013–1022CrossRef
4.
Clowes JA, Peel NFA, Eastell R (2004) The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomised controlled trial. J Clin Endocrinol Metab 89:1117–1123PubMedCrossRef
5.
Yood RA, Emani S, Reid JI et al (2003) Compliance with pharmacological therapy for osteoporosis. Osteoporosis Int 14:965–968CrossRef
6.
Silverman S, Siris E, Abbott T et al (2003) Adherence to bisphosphonate therapy is associated with decreased non-vertebral osteoporotic fracture risk. J Bone Miner Res 20 (suppl 1):S286
7.
Weycker D, Macarios D, Edelsberg J et al (2006) Compliance with drug therapy for postmenopausal osteoporosis. Osteoporosis Int 17:1645–1652CrossRef
8.
Compston JE, Seeman E (2006) Compliance with osteoporosis therapy is the weakest link. Lancet 368:2005–2006CrossRef
9.
Miller NH (1997) Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med 102:43–49PubMedCrossRef
10.
Willey C, Redding C, Stafford J et al (2000) Stages of change for adherence with medication regimens for chronic diseases: development and validation of a measure. Clin Ther 22:858–871PubMedCrossRef
11.
Donovan JL (1995) Patient decision making. The missing ingredient in compliance research. Int J Technol Assess Health Care 11:443–455PubMed
12.
13.
Lutfey KE, Wishner WJ (1999) Beyond “compliance” is “adherence”. Improving the prospect of diabetes care. Diabetes Care 22:635–639PubMedCrossRef
14.
15.
Madden BP (1990) The hybrid model for concept development: its value for the study of therapeutic alliance. ANS Adv Nurs Sci 12:75–87PubMed
16.
Mullen PD (1997) Compliance becomes concordance. B Med J 314:691–692
17.
McCombs JS, Thiebaudet P, McLaughlin-Milet C et al (2004) Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48:271–287PubMedCrossRef
18.
Cooper A, Drake J, Brankin E, on behalf of the persist investigators (2006) Treatment persistence with once-monthly ibandronate and patient support vs. once weekly alendronate: results from the PERSIST study. J Clin Practice 60:896–905CrossRef
19.
Cramer JA, Amonkar MM, Hebborn A et al (2005) Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 21:1453–1460PubMedCrossRef
20.
Fardellone P, Gaudin AF, Cotte FE (2005) Comparison of the persistence of daily and weekly bisphosphonates in female patients treated for osteoporosis. J Bone Miner Res 20 (Suppl 1):S285–S286
21.
Solomon DH, Avorn J, Katz et al (2005) Compliance with osteoporosis indications. Arch Intern Med 165:2414–2419PubMedCrossRef
22.
Docherty SM, Goodley A, Steel SA (2005) Compliance and effect of bone protective treatment in elderly females: 5 year follow-up study. Rheumatology 44(Suppl 1):134
23.
Tosteson ANA, Grove MR, Hammond CS et al (2003) Early discontinuation of treatment for osteoporosis. Am J Med 115:209–216PubMedCrossRef
24.
Hamilton B, McCoy K, Taggart H (2003) Tolerability and compliance with risedronate in clinical practice. Osteoporosis Int 14:259–262
25.
Prowse D, McGetrick V, Thompson AJ et al (2005) Persistence with oral therapy is high amongst patients followed in a DGH osteoporosis. Clinical Rheumatology 44(Suppl):135CrossRef
26.
Briesacher BA, Andrade S, Kahler K et al (2006) Economic impact of the previous year’s adherence with bisphosphonates. J Bone Miner Res 21(suppl 1):S171
27.
World Health Organization (2003) Adherence to long-term therapies: Evidence for action. WHO, Geneva, Switzerland
28.
Lamberg L (2000) Patient-physician relationship critical even during brief “medication checks”. JAMA 284:29–31PubMedCrossRef
29.
Eraker SA, Kirscht JP, Becker MH (1984) Understanding and improving patient compliance. Ann Intern Med 100:258–268PubMed
30.
Ammassari A, Trotta MP, Murri R et al (2002) Study group correlates and predictors of adherence to highly active antiretroviral therapy: Overview of Published. JAIDS 31(suppl 3):S123–S127PubMed
31.
McCloskey E, de Takats D, Orgee J et al (2005) Characteristics associated with non-persistence during daily therapy. Experience from the placebo wing of a community-based clinical trial. J Bone Miner Res 20(suppl 1):S282
32.
Claxton AJ, Cranmer J, Pierce C (2001) A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23:1296–1310PubMedCrossRef
33.
Thompson P, Cooper C, Carr A (2005) Factors influencing adherence to bisphosphonates for osteoporosis. J Bone Miner Res 20 (suppl):S394
34.
Irvine J, Baker B, Smith J et al (1999) Poor adherence to placebo or amiodarone therapy predicts mortality: results from the CAMIAT study Psychosom Med 61:566–575PubMed
35.
Granger BB, Swedberg K, Ekman I, for the CHARM investigators (2005) Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet 366:2005–2011PubMedCrossRef
36.
Delmas PD, Vrijens B, Eastell R et al (2007) Improving measurements of persistence on actonel treatment (IMPACT) investigators. Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 92:296–304CrossRef
37.
Cramer JA, Silverman S (2006) Persistence with Bisphosphonate Treatment for Osteoporosis: Finding the root of the problem. Am J Med 119:S12–S17PubMedCrossRef
38.
Kanis JA et al (2007) Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 11:1–256
39.
40.
Spilker B (1991) Methods of assessing and improving patient compliance in clinical trials. In: Cramer JA, Spilker B (eds) (1991) Patient compliance in medical practice and clinical trials. Raven press, New York pp 37–56
41.
Melnikow J, Kiefe C (1994) Patient compliance and medical research. Issues in methodology. J Gen Int Med 9:96–105CrossRef
42.
Turbi C, Herrero-Beaumont G, Acebes JC et al (2004) Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: An open-label, prospective, nonrandomized, observational study. Clin Ther 26:245–256PubMedCrossRef
43.
Farmer KC (1999) Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther 21:1074–1090PubMedCrossRef
44.
Straka RJ, Fish JT, Benson SR et al (1997) Patient self-reporting of compliance does not correspond with electronic monitoring: an evaluation using isosorbide dinitrate as a model drug. Pharmacotherapy 17:126–132PubMed
45.
Lee JY, Kusek JW, Greene PG et al (1996) Assessing medication adherence by pill count and electronic monitoring in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Am J Hypertens 9:719–725PubMedCrossRef
46.
Mason BJ, Matsuyama JR, Jue SG (1995) Assessment of sulfonylurea adherence and metabolic control. Diabetes Educ 21:52–57PubMedCrossRef
47.
Paes AH, Bakker A, Soe-Agnie CJ (1998) Measurement of patient compliance. Pharm World Sci 20:73–77PubMedCrossRef
48.
Pullar T, Feely M (1990) Problems of compliance with drug treatment: new solutions? Pharm J 245:213–215
49.
Schwed A, Fallab CL, Burnier M et al (1999) Electronic monitoring of compliance to lipid-lowering therapy in clinical practice. J Clin Pharmacol 39:402–409PubMedCrossRef
Metadata
Title
Adherence to treatment of osteoporosis: a need for study
Authors
F. Lekkerkerker
J. A. Kanis
N. Alsayed
G. Bouvenot
N. Burlet
D. Cahall
A. Chines
P. Delmas
R.-L. Dreiser
D. Ethgen
N. Hughes
J.-M. Kaufman
S. Korte
G. Kreutz
A. Laslop
B. Mitlak
V. Rabenda
R. Rizzoli
A. Santora
R. Schimmer
Y. Tsouderos
P. Viethel
J.-Y. Reginster
Publication date
01-10-2007
Publisher
Springer-Verlag
Published in
Osteoporosis International / Issue 10/2007
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-007-0410-4

Other articles of this Issue 10/2007

Osteoporosis International 10/2007 Go to the issue

Original Article

Muscle mass deficits are associated with bone mineral density in men with idiopathic vertebral fracture

Original Article

Homocysteine and fracture risk in postmenopausal women: the OFELY study

Original Article

Simple, novel physical activity maintains proximal femur bone mineral density, and improves muscle strength and balance in sedentary, postmenopausal Caucasian women

Short Communication

Corticosteroid-induced osteoporosis prevention: longitudinal practice patterns in The Netherlands 2001–2005

Original Article

Effect of low-intensity back exercise on quality of life and back extensor strength in patients with osteoporosis: a randomized controlled trial

Original Article

Associations between the metabolic syndrome and bone health in older men and women: the Rancho Bernardo Study